S&P 500   4,584.04 (+0.37%)
DOW   36,214.10 (+0.25%)
QQQ   389.12 (+0.47%)
AAPL   193.16 (-0.13%)
MSFT   372.86 (+0.09%)
META   319.42 (+0.36%)
GOOGL   131.54 (+0.42%)
AMZN   146.24 (-0.44%)
TSLA   243.25 (+1.90%)
NVDA   469.07 (+0.73%)
NIO   7.65 (+2.96%)
BABA   72.07 (-0.43%)
AMD   120.60 (+1.88%)
T   17.04 (-1.05%)
F   10.77 (+1.60%)
MU   74.46 (+1.04%)
CGC   0.67 (+1.04%)
GE   122.20 (+1.64%)
DIS   90.94 (+0.17%)
AMC   7.02 (+0.00%)
PFE   29.11 (+0.07%)
PYPL   58.38 (+0.79%)
XOM   100.29 (-0.15%)
S&P 500   4,584.04 (+0.37%)
DOW   36,214.10 (+0.25%)
QQQ   389.12 (+0.47%)
AAPL   193.16 (-0.13%)
MSFT   372.86 (+0.09%)
META   319.42 (+0.36%)
GOOGL   131.54 (+0.42%)
AMZN   146.24 (-0.44%)
TSLA   243.25 (+1.90%)
NVDA   469.07 (+0.73%)
NIO   7.65 (+2.96%)
BABA   72.07 (-0.43%)
AMD   120.60 (+1.88%)
T   17.04 (-1.05%)
F   10.77 (+1.60%)
MU   74.46 (+1.04%)
CGC   0.67 (+1.04%)
GE   122.20 (+1.64%)
DIS   90.94 (+0.17%)
AMC   7.02 (+0.00%)
PFE   29.11 (+0.07%)
PYPL   58.38 (+0.79%)
XOM   100.29 (-0.15%)
S&P 500   4,584.04 (+0.37%)
DOW   36,214.10 (+0.25%)
QQQ   389.12 (+0.47%)
AAPL   193.16 (-0.13%)
MSFT   372.86 (+0.09%)
META   319.42 (+0.36%)
GOOGL   131.54 (+0.42%)
AMZN   146.24 (-0.44%)
TSLA   243.25 (+1.90%)
NVDA   469.07 (+0.73%)
NIO   7.65 (+2.96%)
BABA   72.07 (-0.43%)
AMD   120.60 (+1.88%)
T   17.04 (-1.05%)
F   10.77 (+1.60%)
MU   74.46 (+1.04%)
CGC   0.67 (+1.04%)
GE   122.20 (+1.64%)
DIS   90.94 (+0.17%)
AMC   7.02 (+0.00%)
PFE   29.11 (+0.07%)
PYPL   58.38 (+0.79%)
XOM   100.29 (-0.15%)
S&P 500   4,584.04 (+0.37%)
DOW   36,214.10 (+0.25%)
QQQ   389.12 (+0.47%)
AAPL   193.16 (-0.13%)
MSFT   372.86 (+0.09%)
META   319.42 (+0.36%)
GOOGL   131.54 (+0.42%)
AMZN   146.24 (-0.44%)
TSLA   243.25 (+1.90%)
NVDA   469.07 (+0.73%)
NIO   7.65 (+2.96%)
BABA   72.07 (-0.43%)
AMD   120.60 (+1.88%)
T   17.04 (-1.05%)
F   10.77 (+1.60%)
MU   74.46 (+1.04%)
CGC   0.67 (+1.04%)
GE   122.20 (+1.64%)
DIS   90.94 (+0.17%)
AMC   7.02 (+0.00%)
PFE   29.11 (+0.07%)
PYPL   58.38 (+0.79%)
XOM   100.29 (-0.15%)

Ionis Pharmaceuticals Stock Price, News & Analysis (NASDAQ:IONS)

$49.89
-0.11 (-0.22%)
(As of 09:40 AM ET)
Compare
Today's Range
$49.80
$50.21
50-Day Range
$43.39
$51.63
52-Week Range
$32.69
$51.89
Volume
11,738 shs
Average Volume
1.06 million shs
Market Capitalization
$7.16 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.23

Ionis Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Hold
2.46 Rating Score
Upside/​Downside
3.3% Downside
$48.23 Price Target
Short Interest
Bearish
6.95% of Float Sold Short
Dividend Strength
N/A
Sustainability
-3.58
Upright™ Environmental Score
News Sentiment
0.82mentions of Ionis Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$934,603 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.46) to ($3.88) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.64 out of 5 stars

Medical Sector

856th out of 948 stocks

Pharmaceutical Preparations Industry

389th out of 419 stocks


IONS stock logo

About Ionis Pharmaceuticals Stock (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California.

IONS Stock Price History

IONS Stock News Headlines

Ionis Pharmaceuticals: Pioneering Precision Medicine
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Ionis reports third quarter 2023 financial results
See More Headlines
Receive IONS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/28/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:IONS
CUSIP
46433010
Employees
796
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$48.23
High Stock Price Target
$67.00
Low Stock Price Target
$27.00
Potential Upside/Downside
-3.5%
Consensus Rating
Hold
Rating Score (0-4)
2.46
Research Coverage
13 Analysts

Profitability

Net Income
$-269,720,000.00
Pretax Margin
-61.06%

Debt

Sales & Book Value

Annual Sales
$587 million
Book Value
$4.03 per share

Miscellaneous

Free Float
139,670,000
Market Cap
$7.17 billion
Optionable
Optionable
Beta
0.49
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives















IONS Stock Analysis - Frequently Asked Questions

Should I buy or sell Ionis Pharmaceuticals stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 2 sell ratings, 4 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" IONS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares.
View IONS analyst ratings
or view top-rated stocks.

What is Ionis Pharmaceuticals' stock price target for 2024?

13 Wall Street research analysts have issued 1 year price targets for Ionis Pharmaceuticals' shares. Their IONS share price targets range from $27.00 to $67.00. On average, they predict the company's share price to reach $48.23 in the next twelve months. This suggests that the stock has a possible downside of 3.3%.
View analysts price targets for IONS
or view top-rated stocks among Wall Street analysts.

How have IONS shares performed in 2023?

Ionis Pharmaceuticals' stock was trading at $37.77 at the beginning of the year. Since then, IONS stock has increased by 32.1% and is now trading at $49.89.
View the best growth stocks for 2023 here
.

When is Ionis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our IONS earnings forecast
.

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) posted its quarterly earnings results on Thursday, November, 2nd. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($1.01) by $0.02. The business earned $144 million during the quarter, compared to analysts' expectations of $139.42 million. Ionis Pharmaceuticals had a negative trailing twelve-month return on equity of 90.50% and a negative net margin of 66.34%.

What other stocks do shareholders of Ionis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (14.98%), Clearbridge Investments LLC (3.37%), Tweedy Browne Co LLC (2.45%), ARK Investment Management LLC (1.65%), Wellington Management Group LLP (1.23%) and Charles Schwab Investment Management Inc. (0.87%). Insiders that own company stock include Allene M Diaz, B Lynne Parshall, Brett P Monia, Brian Birchler, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke.
View institutional ownership trends
.

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:IONS) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -